



Single user / Non-Library usage

US\$ 89.00

Print-On-Demand (P.O.D)

US\$ 107.00

Multi user / Library usage

US\$ 151.00

Editor:

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK

eISBN: 978-1-68108-233-2

Advances in Cancer Drug Targets (Volume 3)

About the eBook

Advances in Cancer Drug Targets is an e-book series that brings together recent expert reviews published on the subject with a focus on strategies for synthesizing and isolating organic compounds and elucidating the structure and nature of DNA.

The reviews presented in this series are written by experts in pharmaceutical sciences and molecular biology. These reviews have been carefully selected to present development of new approaches to anti-cancer therapy and anti-cancer drug development.

Contents

- ▶ Neutrophil Elastase as a Target in Lung Cancer: the State of the Art
- ▶ Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack
- ▶ Points of Therapeutic Intervention along the Wnt Signaling Pathway in Hepatocellular Carcinoma
- ▶ Collaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer
- ▶ Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
- ▶ Melatonin Inhibits the Growth of DMBA-induced Mammary Tumors by Regulating Estrogen Sulfatase Enzyme
- ▶ Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
- ▶ Structure-Activity Studies on Arylamides and Arylsulfonamides Ras Inhibitors

For Sales and Advertising Inquiries: Contact: marketing@benthamscience.net